Winchester, MA, United States of America

Thomas C K Chan

This inventor holds 2 USPTO granted patents. Top assignee: Arqule, Inc.. Active years: 2013-2017.


% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Thomas C K Chan: Innovator in Cancer Treatment

Introduction

Thomas C K Chan is a notable inventor based in Winchester, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Chan's work focuses on developing effective methods for treating cell proliferative disorders.

Latest Patents

Chan's latest patents include groundbreaking methods for treating various types of cancer. One of his inventions provides methods for treating a cell proliferative disorder, such as cancer, by administering a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a second anti-proliferative agent. Another patent specifically addresses the treatment of lung cancer and breast cancer, utilizing similar compounds in conjunction with agents like gemcitabine.

Career Highlights

Chan is currently associated with Arqule, Inc., where he continues to advance his research in cancer therapies. His work has been instrumental in developing new treatment options that could potentially improve patient outcomes.

Collaborations

Throughout his career, Chan has collaborated with esteemed colleagues, including Dennis S France and Giovanni Abbadessa. These partnerships have fostered a collaborative environment that enhances innovation and research in cancer treatment.

Conclusion

Thomas C K Chan's contributions to cancer treatment through his patents and research are commendable. His innovative approaches hold promise for improving therapeutic strategies against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…